Navigation Links
Sinovac Files Annual Report on Form 20-F
Date:4/22/2011

BEIJING, April 22, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today it has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2010 on April 22, 2011.  The Annual Report on Form 20-F is now available on www.sec.gov.

The Company will provide a hard copy of its complete audited financial statements to its shareholders free of charge upon request. Requests for a hard copy of the 2010 annual report can be processed by visiting the Investor Relations section of the Company's website and filling in the complete mailing details on the Contact IR page. 

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel:  +86-10-8279-9871/9659
Fax:  +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington/Amy Glynn
The Ruth Group
Tel:  +1-646-536-7017/7023
Email: scarrington@theruthgroup.com
aglynn@theruthgroup.com

Media
Jason Rando
The Ruth Group
Tel:  +1-646-536-7025
Email:  jrando@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Participates in UBS Greater China Healthcare Corporate Day
2. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
3. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
4. Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range
5. Sinovacs Stock Exchange Listing Moves to NASDAQ Global Select Market
6. Sinovac Receives SFDA Approval to Commence Clinical Trials for Inactivated Enterovirus Type 71 Vaccine
7. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
8. Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
9. Sinovac Receives Drug Registration Certificate from Hong Kong Department of Health for Seasonal Flu Vaccine Anflu(R)
10. Sinovac to Host Conference Call to Report Second Quarter 2010 Financial Results
11. Sinovac Holds 2010 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve ... his tenure, Paul has served us in multiple leadership roles ... Pharmacy in Jun. 2015 and has provided decisive, strategic leadership ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... 2, 2017  Life Flight Network and PeaceHealth Oregon Network ... patient care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, ... and Life Flight Network work collaboratively to move patients who ... when a time sensitive emergency exists. ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Connexion Point, a technology-enabled healthcare services ... the fourth consecutive year. With 197% revenue growth over the past three ... fastest growing companies. , Previous honors include ranking 86th on the Inc. ...
(Date:8/16/2017)... ... 2017 , ... First Choice Emergency Room , the largest network of ... the new Medical Director of its Sienna Plantation facility. , “We are pleased ... Plantation location,” said Dr. Michael (Derek) Caraway, Area Medical Director of First Choice Emergency ...
(Date:8/16/2017)... ... ... Every Chain”: an inspirational story for those shackled by the chains of a broken life. ... a writer and a woman of great faith and wisdom. She is a great ... was born and raised in Vero Beach, Florida and has dedicated her life and ministry ...
(Date:8/15/2017)... ... August 15, 2017 , ... The first study to report that overall ... been completed, with the team’s findings now published online ahead of print in the ... the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, was principal investigator ...
(Date:8/15/2017)... ... , ... Progressive Dental, a leading dental marketing and consulting firm ... of Fastest Growing Companies in Tampa Bay. The Tampa Bay Business Journal creates this ... years of growth. For this year’s award, Progressive Dental ranked number 29, with a ...
Breaking Medicine News(10 mins):